NuCana (NCNA) Gains from Investment Securities (2017 - 2025)

NuCana (NCNA) reported Gains from Investment Securities of $16.5 million for Q4 2025, up 198.58% sequentially from -$16.8 million in Q3 2025.

NuCana (NCNA) Gains from Investment Securities (2017 - 2025) Analysis & Trends

NuCana (NCNA) has 5 years of Gains from Investment Securities data on file, last reported at $16.5 million in Q4 2025.

For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to $16.5 million; the trailing twelve-month figure through Dec 2025 stood at $1.4 million (changed N/A YoY), and the FY2025 full-year result was $16.7 million, changed N/A from the prior year.
Gains from Investment Securities rose to $16.5 million in Q4 2025, from -$16.8 million in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $16.5 million in Q4 2025 to a low of -$16.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,132.22 Bn	67,131.94 Bn	-
2	Nanobiotix	1,910.87 Bn	1,910.81 Bn	-
3	Akari Therapeutics	989.71 Bn	989.71 Bn	-
4	BeOne Medicines	471.60 Bn	466.80 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.71 Bn	114.46 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.83 Bn	61.07 Bn	3.31 Bn
7	Belite Bio	62.74 Bn	62.74 Bn	-
8	Argenx Se	55.83 Bn	50.65 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.33 Bn	34.32 Bn	959.66 Mn
10	NuCana	14.77 Bn	14.74 Bn	-

Download Data